about
Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppressionDeleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activityTensin2 variant 3 is associated with aggressive tumor behavior in human hepatocellular carcinomaDeleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinomaNuclear-targeted deleted in liver cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivoElevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-κB signaling.ANXA3/JNK Signaling Promotes Self-Renewal and Tumor Growth, and Its Blockade Provides a Therapeutic Target for Hepatocellular Carcinoma.Role and significance of focal adhesion proteins in hepatocellular carcinoma.Targeting estrogen-related receptor alpha inhibits epithelial-to-mesenchymal transition and stem cell properties of ovarian cancer cellsMechanisms through Which Hypoxia-Induced Caveolin-1 Drives Tumorigenesis and Metastasis in Hepatocellular Carcinoma.Krüppel-like factor 4 (KLF4) suppresses neuroblastoma cell growth and determines non-tumorigenic lineage differentiation.Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma.Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.Genomic structure, alternative splicing and tissue expression of rFrp/sFRP-4, the rat frizzled related protein gene.Nuclear Met promotes hepatocellular carcinoma tumorigenesis and metastasis by upregulation of TAK1 and activation of NF-κB pathway.C-terminal truncated HBx protein activates caveolin-1/LRP6/β-catenin/FRMD5 axis in promoting hepatocarcinogenesisGalectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cellsCAMK2A supported tumor initiating cells of lung adenocarcinoma by upregulating SOX2 through EZH2 phosphorylation
P50
Q24301470-CCD8BAAB-E327-442E-B038-25B16FFAED84Q24533631-2AD2E34B-89EB-44A2-BDBF-905ACE9317B5Q28265813-E20256C4-0F7B-409B-B2C1-EE187FF18A59Q33354161-7E38B3A0-6DFC-48E8-933A-446388C13E71Q34038402-30865F7B-6D54-4F4C-8E15-A3D7B99CA540Q34365776-02B79837-31EE-4C13-8029-D8BD04262E3AQ36200984-C706A1AD-7DB5-487C-813D-A92BDD80ABFFQ37445115-B3DA5534-B82C-441B-90B5-0472875D23DDQ37696020-F19AA459-B073-49F3-BA1E-5D3DF6689E51Q38290466-74064613-D1C2-43C9-83EA-CF5463483091Q39263949-D10ED14F-146F-4DBB-A56B-A2BD38BF4C67Q39782036-9D4FEEE5-9E0E-4524-986E-115654EA472DQ40365802-99EB8379-55CF-4863-BBA9-B4A49B709D98Q42661927-99172C87-8FBC-403E-ACB1-12EC0862E479Q47680404-24C3C635-6C5D-4A4D-A2BC-B400BDDB4029Q90739391-467352D6-1406-483C-B3B0-559BDF64D03DQ90880719-01AFD094-1908-4E0D-9E7F-0EA48642A9ECQ96126115-00EF5E25-5648-41DD-9162-7F296CEA3576
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Judy Wai Ping Yam
@ast
Judy Wai Ping Yam
@en
Judy Wai Ping Yam
@es
Judy Wai Ping Yam
@nl
type
label
Judy Wai Ping Yam
@ast
Judy Wai Ping Yam
@en
Judy Wai Ping Yam
@es
Judy Wai Ping Yam
@nl
prefLabel
Judy Wai Ping Yam
@ast
Judy Wai Ping Yam
@en
Judy Wai Ping Yam
@es
Judy Wai Ping Yam
@nl
P106
P1153
6603711123
P31
P496
0000-0002-5637-121X